Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 238

The DOI matches its Crossref record.

The BRAF mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma

Kim, Tae Yong, Kim, Won Bae, Rhee, Yoon Soo, Song, Ja Young, Kim, Jung Min, Gong, Gyungyub, Lee, Seungkoo, Kim, Sang Yoon, Kim, Seong Chul, Hong, Suck Joon, Shong, Young Kee·2006·Clinical Endocrinology

Abstract

Summary: Background The activating BRAFV600E mutation is the most common genetic alteration reported in papillary thyroid carcinoma (PTC). While some reports suggest the BRAFV600E mutation is associated with factors predicting a poor prognosis and recurrence, this remains a controversial issue. Aim To determine whether the presence of the BRAFV600E mutation is a prognostic indicator for clinical recurrence in low‐risk patients with conventional PTC. Patients and methods The study involved 203 conventional PTC patients who underwent total or near‐total thyroidectomy followed by immediate 131 I ablation of the remnants. Patients with antithyroglobulin antibodies and those with extracervical metastases at presentation were excluded. DNA was extracted from paraffin‐embedded tumour specimens, and the presence of the BRAFV600E mutation was evaluated using PCR amplification and direct sequencing. Results The BRAFV600E mutation was found to be present in 149 (73·4%) of 203 patients. The BRAFV600E mutation was correlated with male gender (P = 0·006) and with tumour size (P = 0·005). While there appeared to be an association between the BRAFV600E mutation and extrathyroid extension, this did not reach statistical significance (P = 0·062). During follow‐up of the 203 patients (median 7·3 years; range 0·7–10·0 years), 36 (18%) patients experienced recurrence. While univariate analysis showed the BRAFV600E mutation was associated with tumour recurrence (21% with mutation vs 7% without mutation; P = 0·037), this association was not shown following multivariate analyses adjusting for the clinicopathological prognostic factors of age, gender, tumour size, extrathyroid extension, multifocality and lymph node metastasis. Conclusions Although the BRAFV600E mutation was found to be associated with a higher clinical recurrence of disease in low‐risk conventional PTC patients, it was not an independent predictor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2006.02605.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 238

Metadata

Authors
Kim, T. Y., Kim, W. B., Rhee, Y. S., Song, J. Y., Kim, J. M., Gong, G., Lee, S., Kim, S. Y., Kim, S. C., Hong, S. J., & Shong, Y. K.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2006-07-10
Volume
65
Issue
3
Pages
364-368
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2056671717
Cited by
238
References
0
FWCI
9.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The BRAF mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma. https://app.cochat.ai/papers/10.1111/j.1365-2265.2006.02605.x
The paper
Kim, T. Y., Kim, W. B., Rhee, Y. S., Song, J. Y., Kim, J. M., Gong, G., Lee, S., Kim, S. Y., Kim, S. C., Hong, S. J., & Shong, Y. K. (2006). The BRAF mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2006.02605.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.